Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Quince Therapeutics Inc (QNCX)

Quince Therapeutics Inc (QNCX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 39,110
  • Shares Outstanding, K 43,215
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,390 K
  • 60-Month Beta 1.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.54
Trade QNCX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.84
  • Most Recent Earnings $-0.26 on 05/13/24
  • Latest Earnings Date 05/20/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 1,432.41% ( +1,432.41%)
  • Historical Volatility 55.46%
  • IV Percentile 99%
  • IV Rank 100.00%
  • IV High 1,432.41% on 05/17/24
  • IV Low 34.09% on 06/21/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 31
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,030
  • Open Int (30-Day) 988

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8996 +0.60%
on 05/14/24
1.1200 -19.20%
on 04/30/24
-0.0950 (-9.50%)
since 04/17/24
3-Month
0.8900 +1.69%
on 04/12/24
1.4200 -36.27%
on 02/26/24
-0.3750 (-29.30%)
since 02/16/24
52-Week
0.8400 +7.74%
on 11/20/23
1.7400 -47.99%
on 05/22/23
-0.6850 (-43.08%)
since 05/17/23

Most Recent Stories

More News
Quince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake Capital

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that its...

QNCX : 0.9050 (-1.62%)
Quince Therapeutics Engages MTS Health Partners as Independent Financial Advisor

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that it...

QNCX : 0.9050 (-1.62%)
Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that its...

QNCX : 0.9050 (-1.62%)
Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today confirmed that it...

QNCX : 0.9050 (-1.62%)
Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today provided an update...

QNCX : 0.9050 (-1.62%)
Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced the sale of the company’s legacy...

QNCX : 0.9050 (-1.62%)
Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone Injury

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company’s...

QNCX : 0.9050 (-1.62%)
Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company’s...

QNCX : 0.9050 (-1.62%)
Quince Therapeutics Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today presented preclinical data at the 14 th...

QNCX : 0.9050 (-1.62%)
Quince Therapeutics to Present at Upcoming Scientific Meetings

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced that the company will present at a...

QNCX : 0.9050 (-1.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Quince Therapeutics Inc. is a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases. The company's product pipeline includes NOV004. Quince Therapeutics Inc., formerly known as Cortexyme Inc., is based in Calif.

See More

Key Turning Points

3rd Resistance Point 1.0200
2nd Resistance Point 0.9950
1st Resistance Point 0.9500
Last Price 0.9050
1st Support Level 0.8800
2nd Support Level 0.8550
3rd Support Level 0.8100

See More

52-Week High 1.7400
Fibonacci 61.8% 1.3962
Fibonacci 50% 1.2900
Fibonacci 38.2% 1.1838
Last Price 0.9050
52-Week Low 0.8400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar